Form 8-K - Current report:
SEC Accession No. 0001628280-25-014136
Filing Date
2025-03-20
Accepted
2025-03-20 16:31:51
Documents
14
Period of Report
2025-03-20
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20250320.htm   iXBRL 8-K 34982
2 EX-1.1 fhtx-atmxamendmentno1tosal.htm EX-1.1 53424
  Complete submission text file 0001628280-25-014136.txt   226667

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20250320.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20250320_lab.xml EX-101.LAB 22543
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20250320_pre.xml EX-101.PRE 13047
16 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20250320_htm.xml XML 2829
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 25756946
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)